INSULET CORP (PODD) Stock Price & Overview

NASDAQ:PODD • US45784P1012

219.84 USD
-16.23 (-6.88%)
At close: Mar 13, 2026
219.84 USD
0 (0%)
After Hours: 3/13/2026, 8:00:00 PM

The current stock price of PODD is 219.84 USD. Today PODD is down by -6.88%. In the past month the price decreased by -8.71%. In the past year, price decreased by -13.94%.

PODD Key Statistics

52-Week Range216.49 - 354.88
Current PODD stock price positioned within its 52-week range.
1-Month Range216.49 - 275.1
Current PODD stock price positioned within its 1-month range.
Market Cap
15.477B
P/E
44.23
Fwd P/E
34.00
EPS (TTM)
4.97
Dividend Yield
N/A

PODD Stock Performance

Today
-6.88%
1 Week
-7.24%
1 Month
-8.71%
3 Months
-25.65%
Longer-term
6 Months -35.68%
1 Year -13.94%
2 Years +28.26%
3 Years -31.08%
5 Years -15.74%
10 Years +562.97%

PODD Stock Chart

INSULET CORP / PODD Daily stock chart

PODD Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to PODD. When comparing the yearly performance of all stocks, PODD is a bad performer in the overall market: 83.12% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
PODD Full Technical Analysis Report

PODD Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to PODD. PODD gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PODD Full Fundamental Analysis Report

PODD Earnings

On February 18, 2026 PODD reported an EPS of 1.55 and a revenue of 783.80M. The company beat EPS expectations (4.5% surprise) and missed revenue expectations (-0.03% surprise).

Next Earnings DateMay 6, 2026
Last Earnings DateFeb 18, 2026
PeriodQ4 / 2025
EPS Reported$1.55
Revenue Reported783.8M
EPS Surprise 4.50%
Revenue Surprise -0.03%
PODD Earnings History

PODD Forecast & Estimates

34 analysts have analysed PODD and the average price target is 363.98 USD. This implies a price increase of 65.57% is expected in the next year compared to the current price of 219.84.

For the next year, analysts expect an EPS growth of 30.08% and a revenue growth 22.61% for PODD


Analysts
Analysts85.29
Price Target363.98 (65.57%)
EPS Next Y30.08%
Revenue Next Year22.61%
PODD Forecast & Estimates

PODD Groups

Sector & Classification

PODD Financial Highlights

Over the last trailing twelve months PODD reported a non-GAAP Earnings per Share(EPS) of 4.97. The EPS increased by 49.25% compared to the year before.


Income Statements
Revenue(TTM)2.71B
Net Income(TTM)247.10M
Industry RankSector Rank
PM (TTM) 9.12%
ROA 7.75%
ROE 16.31%
Debt/Equity 0.61
Chartmill High Growth Momentum
EPS Q2Q%34.78%
Sales Q2Q%31.18%
EPS 1Y (TTM)49.25%
Revenue 1Y (TTM)30.73%
PODD financials

PODD Ownership

Ownership
Inst Owners103.04%
Shares70.40M
Float69.87M
Ins Owners0.34%
Short Float %2.16%
Short Ratio1.6
PODD Ownership

PODD Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES18.81187.913B
ISRG INTUITIVE SURGICAL INC46.2170.203B
SYK STRYKER CORP22.27129.047B
BSX BOSTON SCIENTIFIC CORP19.77101.721B
EW EDWARDS LIFESCIENCES CORP27.5249.099B
IDXX IDEXX LABORATORIES INC38.7145.48B
BDX BECTON DICKINSON AND CO11.6945.453B
RMD RESMED INC18.833.857B
GEHC GE HEALTHCARE TECHNOLOGY13.6932.053B
DXCM DEXCOM INC25.2725.116B
ZBH ZIMMER BIOMET HOLDINGS INC10.9918.115B
HOLX HOLOGIC INC15.316.79B

About PODD

Company Profile

PODD logo image Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 5,400 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

Company Info

IPO: 2007-05-15

INSULET CORP

100 Nagog Park

Acton MASSACHUSETTS 01720 US

CEO: Shacey Petrovic

Employees: 5400

PODD Company Website

PODD Investor Relations

Phone: 19786007000

INSULET CORP / PODD FAQ

Can you describe the business of INSULET CORP?

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 5,400 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.


What is the current price of PODD stock?

The current stock price of PODD is 219.84 USD. The price decreased by -6.88% in the last trading session.


Does INSULET CORP pay dividends?

PODD does not pay a dividend.


How is the ChartMill rating for INSULET CORP?

PODD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


What sector and industry does INSULET CORP belong to?

INSULET CORP (PODD) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


Can you provide the ownership details for PODD stock?

You can find the ownership structure of INSULET CORP (PODD) on the Ownership tab.